恩格列净联合二甲双胍治疗2型糖尿病的效果评价

Efficacy Evaluation of Empagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus

目的 分析恩格列净联合二甲双胍治疗2型糖尿病的效果。方法 选取2021年3月—2022年4月厦门大学附属第一医院同安院区(厦门市第三医院)收治的98例2型糖尿病患者为研究对象,按照随机数表法分为观察组和对照组,每组49例。两组均予以二甲双胍治疗,同时观察组加行恩格列净治疗。比较两组血糖水平、血脂水平、胰岛β细胞功能、不良反应发生率以及临床疗效。结果 治疗6个月后,与对照组相比,观察组血糖水平、血脂水平均较低,胰岛β细胞功能的改善情况较好,差异有统计学意义(P<0.05)。观察组不良反应发生率8.16%与对照组6.12%对比,差异无统计学意义(P>0.05)。观察组治疗总有效率95.92%较对照组83.67%更高,差异有统计学意义(P<0.05)。结论 应用恩格列净联合二甲双胍治疗,效果突出,可有效调节糖脂代谢,纠正胰岛β细胞功能。

Objective To analyze the effect of Empagliflozin combined with metformin in the treatment of type 2 diabetes mellitus.Methods From March 2021 to April 2022,98 patients with type 2 diabetes treated in Tong 'an District the First Affiliated Hospital of Xiamen University(Xiamen Third Hospital) were selected as the research objects.According to the random number table method,they were divided into observation group and control group,49 cases in each group.Both groups were treated with metformin,while the observation group was treated with empagliflozin.The blood glucose level,blood lipid level,islet β cell function,incidence of adverse reactions and clinical efficacy were compared between the two groups.Results After 6 months of treatment,compared with the control group,the blood glucose level and blood lipid level in the observation group were lower,and the improvement of islet β cell function was better,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group(8.16%) and the control group(6.12%)(P>0.05).The total effective rate of treatment in the observation group was 95.92% higher than that in the control group(83.67%),and the difference was statistically significant(P<0.05).Conclusion The treatment of Empagliflozin combined with metformin has a remarkable effect,which can effectively regulate the metabolism of glucose and lipid and correct the function of islet beta cells.